La Jolla Pharmaceutical Company EBITDA 2011-2026 | LJPC

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA La Jolla Pharmaceutical Company

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
21.9 M	-31.8 M	-105 M	-190 M	-114 M	-77.6 M	-41.6 M	-21.3 M	-17.9 M	-13.7 M	7 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
21.9 M	-190 M	-53.1 M

Quarterly EBITDA La Jolla Pharmaceutical Company

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-1.02 M	-2.02 M	-	925 K	3.85 M	17.5 M	-	-7.37 M	-10.7 M	-9.4 M	-	-23.4 M	-26 M	-28.5 M	-	-45.1 M	-49.5 M	-49.7 M	-38.8 M	-25.6 M	-26.2 M	-23 M	-24.9 M	-20.8 M	-15.3 M	-16.4 M	-11.9 M	-10.4 M	-10.6 M	-8.96 M	-6.86 M	-5.06 M	-4.28 M	-5.13 M	-	-4.17 M	-3.16 M	-4.2 M	-	-3.45 M	-3.21 M	-671 K	-	-423 K	-904 K	-478 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
17.5 M	-49.7 M	-13 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Ultragenyx Pharmaceutical RARE	-500 M	$ 19.23	-3.85 %	$ 1.9 B	USA
ARCA biopharma ABIO	-88.1 M	-	1052.0 %	$ 415 M	USA
RedHill Biopharma Ltd. RDHL	-81.1 M	$ 0.8	0.89 %	$ 428 M	Israel
Dr. Reddy's Laboratories Limited RDY	24.3 B	$ 13.56	-1.56 %	$ 2.25 B	India
Regeneron Pharmaceuticals REGN	4.12 B	$ 742.02	-1.94 %	$ 77.6 B	USA
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-23.9 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
AIkido Pharma AIKI	-11.4 M	-	1.93 %	$ 17.4 M	USA
Akouos AKUS	-84.3 M	-	0.23 %	$ 488 M	USA
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	31.8 M	-	2.54 %	$ 160 B	France
Albireo Pharma ALBO	-123 M	-	-0.23 %	$ 916 M	USA
Replimune Group REPL	-258 M	$ 7.22	-4.24 %	$ 582 M	USA
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
REGENXBIO RGNX	-146 M	$ 7.88	-4.6 %	$ 406 M	USA
Aileron Therapeutics ALRN	-50.6 M	-	10.36 %	$ 9.8 M	USA
Aptinyx APTX	-62.4 M	-	-39.0 %	$ 4.57 M	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Arena Pharmaceuticals ARNA	-620 M	-	-6.81 %	$ 3.04 B	USA
Rigel Pharmaceuticals RIGL	128 M	$ 26.2	-0.64 %	$ 471 M	USA
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
Avenue Therapeutics ATXI	-11.3 M	-	-52.27 %	$ 4.45 M	USA
Ayala Pharmaceuticals AYLA	-37.3 M	-	-	$ 7.46 M	Israel
Atreca BCEL	5.46 M	-	-11.76 %	$ 5.79 M	USA
Avidity Biosciences RNA	-742 M	$ 13.09	-0.08 %	$ 1.8 B	USA
Acorda Therapeutics ACOR	-233 M	-	-24.86 %	$ 820 K	USA
bluebird bio BLUE	-216 M	-	-	$ 546 M	USA
Acasti Pharma ACST	-16.7 M	-	4.01 %	$ 150 M	Canada
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
Avid Bioservices CDMO	-7.57 M	-	-	$ 789 M	USA
Adverum Biotechnologies ADVM	-136 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	-24.5 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	-35.9 M	-	-9.65 %	$ 45.9 M	USA
Rhythm Pharmaceuticals RYTM	-192 M	$ 78.52	-4.13 %	$ 5.1 B	USA
Adaptive Biotechnologies Corporation ADPT	-41.1 M	$ 12.57	-9.96 %	$ 1.91 B	USA
Sana Biotechnology SANA	-238 M	$ 2.78	-8.42 %	$ 704 M	USA
BeiGene, Ltd. BGNE	589 M	-	0.49 %	$ 251 B	Cayman-islands
SIGA Technologies SIGA	24.3 M	$ 5.35	7.76 %	$ 383 M	USA
Alnylam Pharmaceuticals ALNY	557 M	$ 321.71	-1.96 %	$ 42.1 B	USA
BioDelivery Sciences International BDSI	37.3 M	-	-4.8 %	$ 255 M	USA
Cara Therapeutics CARA	-121 M	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	-127 M	-	-	$ 3.74 B	USA
Silence Therapeutics plc SLN	-45.8 M	$ 4.8	-9.6 %	$ 622 M	Britain
Enlivex Therapeutics Ltd. ENLV	-18.7 M	$ 1.08	-0.92 %	$ 22.2 M	Israel
Enochian Biosciences ENOB	-189 M	-	-	$ 40.5 M	USA